Alkylthioacetic acids (3-thia fatty acids) as non-beta-oxidizable fatty acid analogues: a new group of hypolipidemic drugs. III. Dissociation of cholesterol- and triglyceride-lowering effects and the induction of peroxisomal beta-oxidation

J Lipid Res. 1989 Nov;30(11):1711-8.

Abstract

Previous work in this laboratory indicated that sulfur-substituted fatty acid analogues, 1.10-bis(carboxymethylthio)decane and alkylthioacetic acid, both non-beta-oxidizable compounds, and the beta-oxidizable alkylthiopropionic acid (1) caused, to different extents, dose-related hepatomegaly and proliferation of peroxisomes and enhanced peroxisomal fatty acid beta-oxidation. In the present study, treatment of normolipidemic rats with alkylthioacetic acid resulted in a dose- and time-dependent decrease in serum cholesterol and serum and liver triglycerides to an extent comparable to that of the 3-thiadicarboxylic acid. At hypolipidemic doses, alkylthioacetic acid caused no hepatomegaly, did not significantly alter peroxisome morphology, and only marginally affected peroxisomal beta-oxidation activity. Only at the highest, nonpharmacological doses of alkylthioacetic acid were these hepatic parameters increased, although to a lesser extent than by the 3-thiadicarboxylic acid. Hence, on the basis of dose- and time-related studies of the two compounds, data indicate that the hypotriglyceridemia and hypocholesterolemia were dissociated from induction of peroxisomal beta-oxidation and peroxisome proliferation. Palmitic acid and hexadecanedioic acid, both beta-oxidizable fatty acids, only marginally affected the serum and liver parameters. The beta-oxidizable fatty acid analogue, alkylthiopropionic acid lowered the serum triglycerides in normolipidemic rats. In contrast to the 3-thiadicarboxylic acid and alkylthioacetic acid, alkylthiopropionic acid treatment at hypolipidemic doses caused accumulation of triglycerides in the liver.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cholesterol / blood*
  • Cholesterol / metabolism
  • Dicarboxylic Acids / pharmacology
  • Fatty Acids / pharmacology*
  • Liver / drug effects
  • Liver / metabolism
  • Liver / ultrastructure*
  • Male
  • Microbodies / drug effects
  • Microbodies / metabolism*
  • Microbodies / ultrastructure
  • Organ Size / drug effects
  • Oxidation-Reduction
  • Palmitic Acid
  • Palmitic Acids / pharmacology
  • Propionates / pharmacology
  • Rats
  • Rats, Inbred Strains
  • Sulfhydryl Compounds / pharmacology
  • Sulfides / pharmacology*
  • Triglycerides / blood*
  • Triglycerides / metabolism

Substances

  • Dicarboxylic Acids
  • Fatty Acids
  • Palmitic Acids
  • Propionates
  • Sulfhydryl Compounds
  • Sulfides
  • Triglycerides
  • 1-(carboxyethylthio)tetradecane
  • Palmitic Acid
  • 1,10-bis(carboxymethylthiodecane)
  • hexadecanedioic acid
  • Cholesterol